The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...

A new study published in the Journal of American Medical Association showed that rare instances of noninfectious intraocular ...

The quest to find a cure for the UK’s biggest cause of sight loss will be brought sharply into focus at a support group for ...

Researchers led by the University Hospital Zurich have identified cases of sterile intraocular inflammation, including severe retinal vasculitis, associated with faricimab injections used to treat eye ...

The Small Business Innovation Research (SBIR) grant will support the advancement of Investigational New Drug (IND) enabling studies for lead asset ...

Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s ...

Faricimab, a humanized, bispecific, immunoglobulin G monoclonal antibody, received FDA approval as an intravitreal injection ...

Importantly, the appearance of bisretinoids, followed by retinal cell death, and progressive loss of vision is also observed in geographic atrophy (GA) patients. Therefore, Belite Bio is evaluating ...

SOL-1 is now expected to be enrolled and fully randomized by year-end 2024. Topline clinical data from SOL-1 are now expected in Q4 2025. BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWS ...

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) and keeping the ...

Furthermore, Dr. Sherif’s presentation will highlight upcoming near-term milestones, including the topline results from the ACUITY Phase 2 trial with OCS-05 for the treatment of acute optic neuritis, ...